OmniAb, Inc. (OABI) · Oct 30, 2026 · Earnings
Beat — Revenue $3.99M vs ~$3.49M consensus; EPS $0.12 loss vs ~$0.12 loss consensus
OmniAb’s third-quarter earnings beat revenue expectations, while higher 2026 revenue and cash guidance strengthen its platform-expansion story.
OmniAb is trying to shift from a lumpy antibody-discovery licensing model toward a broader platform business built around recurring services, xPloration instruments and consumables, and downstream partner royalties. Its commercial xPloration expansion and partner pipeline were already public, so the new information here is the stronger-than-expected quarter and the higher full-year outlook.
The quarter beat on revenue, but not on per-share losses. Third-quarter revenue was $3.993 million versus published consensus of about $3.49 million, while diluted EPS was a $0.12 loss against consensus of roughly a $0.12 loss. Revenue grew 78% year over year, led mainly by services and xPloration rather than a new quarterly milestone.
| Metric | Q3 2026 | Q3 2025 | Consensus / prior guide |
|---|---|---|---|
| Total revenue (Income Statement) | $3.99M (+78%) | $2.24M | $3.49M |
| Diluted EPS (Income Statement) | $0.12 loss | $0.14 loss | $0.12 loss |
| Revenue guidance (Guidance) | $35M–$39M | — | $32M–$36M prior |
| GAAP operating expenses (Guidance) | $83M–$87M | — | $84M–$88M prior |
| Cash operating expenses (Guidance) | $50M–$54M | — | $51M–$55M prior |
| Year-end cash and equivalents (Guidance) | $53M–$57M | — | $49M–$53M prior |
The more important signal is the guidance raise. OmniAb lifted its 2026 revenue range by $3 million at both ends, lowered projected GAAP and cash operating costs, and raised its expected year-end cash range. That is a cleaner improvement than the quarterly EPS result: management is signaling better revenue conversion and slightly better cost control, not merely repeating the prior plan.
Growth is improving, but it remains uneven and milestone-dependent. Nine-month revenue reached $31.8 million versus $10.3 million a year earlier, but $21.6 million came from license and milestone revenue. In the third quarter, that line contributed only $0.1 million, while services and xPloration supplied most of the growth. The business is therefore expanding beyond one-off milestones, but the recurring base has not yet become large enough to make results smooth.
The operating story is advancing through broader platform monetization. xPloration revenue reached $0.7 million in the quarter, up from $0.07 million, and the company has moved from a limited partner-access model to availability for all customers. Its stated plan to double xPloration revenue in both 2027 and 2028 gives the launch a measurable commercial trajectory, though it remains an expectation rather than established recurring scale.
The partner pipeline adds strategic support, not immediate quarterly revenue. OmniAb ended the period with 111 active partners and 433 active programs, including 34 clinical or commercial programs, and added a Lilly ion-channel collaboration worth up to $370 million in potential milestones plus royalties. 〔0〕 Those economics reinforce the long-term platform thesis, but the contingent milestone value should not be treated as near-term sales.
Bottom line: This is a genuine step forward versus expectations: revenue beat, the loss was in line, and full-year revenue and cash guidance moved higher. The business story is improving, but the quality of growth still depends on converting xPloration and partner activity into steadier recurring revenue rather than relying on sporadic milestones.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!